<DOC>
	<DOCNO>NCT01023308</DOCNO>
	<brief_summary>Panobinostat ( LBH589 ) highly potent pan-deacetylase inhibitor ( pan-DACi ) , inclusive HDAC6 , disrupt aggresome function , promote accumulation cytotoxic misfolded protein aggregate trigger myeloma cell death . Combination pan-DAC proteasome inhibition co-treatment panobinostat ( PAN ) bortezomib ( BTZ ) demonstrate synergistic cytotoxicity vitro vivo pre-clinical experiment . Furthermore , clinical experience advance multiple myeloma ( MM ) patient treated oral panobinostat i.v bortezomib ± dexamethasone show encouraging result efficacy manageable toxicity profile . Given medical need improve treatment strategy patient previously treat relapsed MM , purpose prospective , multinational , randomize , double-blind , placebo-controlled , parallel group Phase III study compare result progression-free survival 2 combination therapy , panobinostat bortezomib dexamethasone placebo bortezomib dexamethasone , patient previously treat MM recur 1-3 prior line therapy</brief_summary>
	<brief_title>Panobinostat Placebo With Bortezomib Dexamethasone Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patient previous diagnosis multiple myeloma . 2 . Patient 13 prior line therapy require retreatment multiple myeloma 3 . Patient measurable disease ( Mprotein ) serum urine study screen 1 . Patient progress prior line anti MM therapy 2 . Patient treat bortezomib , reach least minor response therapy , progress within 60 day last dose 3 . Patient show intolerance bortezomib dexamethasone component drug contraindication one drug , follow locally applicable prescribe information 4 . Patient receive prior treatment DAC inhibitor include panobinostat 5 . Patient impaired cardiac function , prolong QTc interval screen ECG 6 . Patient take medication relative risk prolong QT interval induce Torsade de point 7 . Female patient pregnant breast feed childbearing potential willing use double method contraception 3 month end study treatment . Male patient willing use barrier method contraception 3 month end study treatment . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>DACi</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Combination</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>LBH589D</keyword>
	<keyword>relapse</keyword>
	<keyword>Velcade®</keyword>
</DOC>